Clinical Trial Update: Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating growth and bone mineral density in children with atopic dermatitis treated with dupilumab has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Severe Atopic Dermatitis (AD) | Phase 4 | Status: WITHDRAWN